ConductScience.org, home

Paper39875975

CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.

Shi Q and 4 others. Breast Cancer Res, 2025. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer. Papers, record 39875975. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39875975

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
PubMed
Journal
Breast Cancer Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.25, provisional
iCite
Revised in PubMed
2026-10-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shi QQianfeng
2Yang WWang
3Ouyang YYiye
4Liu YYujie
5Cai ZZijie

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, CXCR4Major topic
Breast NeoplasmsMajor topic
Drug Resistance, NeoplasmMajor topic
Neoplastic Stem CellsMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Female
Animals
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Mice
Xenograft Model Antitumor Assays
Pyridines
Cell Line, Tumor
Receptors, Estrogen
Gene Expression Regulation, Neoplastic
Piperazines
beta Catenin
Cell Proliferation

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2023A1515010127the Natural Science Foundation of GuangdongPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in40001186Correction: CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.https://conductscience.org/library/papers/40001186

Source PubMed

Download CSV of comments and corrections

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12911749820-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.N Engl J Med2017https://conductscience.org/library/papers/29117498PubMed
29694791The regulation of E2F by pRB-family proteins.Genes Dev1998https://conductscience.org/library/papers/9694791PubMed
318467589Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.Science2008https://conductscience.org/library/papers/18467589PubMed
422475046Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.Breast Cancer Res2012https://conductscience.org/library/papers/22475046PubMed
515138475Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.Br J Cancer2004https://conductscience.org/library/papers/15138475PubMed
628303264The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Trends Cancer2017https://conductscience.org/library/papers/28303264PubMed
730345905Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med2018https://conductscience.org/library/papers/30345905PubMed
831563959The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/31563959PubMed
933761995Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.Breast Cancer Res2021https://conductscience.org/library/papers/33761995PubMed
1035263519Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.N Engl J Med2022https://conductscience.org/library/papers/35263519PubMed
1127959613Palbociclib and Letrozole in Advanced Breast Cancer.N Engl J Med2016https://conductscience.org/library/papers/27959613PubMed
1230914635Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.Nat Commun2019https://conductscience.org/library/papers/30914635PubMed
1327748766Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Oncogene2017https://conductscience.org/library/papers/27748766PubMed
1431594766PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.Cancer Discov2020https://conductscience.org/library/papers/31594766PubMed
1530554963Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.Cell Stem Cell2019https://conductscience.org/library/papers/30554963PubMed
1636127291PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness.Cell Prolif2023https://conductscience.org/library/papers/36127291PubMed
1730029203Cancer stem cell in breast cancer therapeutic resistance.Cancer Treat Rev2018https://conductscience.org/library/papers/30029203PubMed
1835301432A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis.Cell Death Differ2022https://conductscience.org/library/papers/35301432PubMed
1930228301Stem cell fate in cancer growth, progression and therapy resistance.Nat Rev Cancer2018https://conductscience.org/library/papers/30228301PubMed
2026390243Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.Nat Med2015https://conductscience.org/library/papers/26390243PubMed

See all 39 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42780585Changes in the metabolism of axillary lymph node cells as a predictor of regional metastasis in breast cancer.World J Exp Med2026https://conductscience.org/library/papers/42780585PubMed
42768738Cancer Stem Cell Quiescence: Molecular and Microenvironmental Evidence for an Actively Regulated Adaptive Survival Strategy.Cancer Med2026https://conductscience.org/library/papers/42768738PubMed
42512259CDK4/6 Inhibitor-Induced Senescence in Cancer: Mechanisms and Therapeutic Implications.Cancers (Basel)2026https://conductscience.org/library/papers/42512259PubMed
41997307Regulation of PSAT1 and PHGDH by m6A in endocrine-resistant breast cancer cells.Biochim Biophys Acta Mol Basis Dis2026https://conductscience.org/library/papers/41997307PubMed
41210649Could circulating tumor cells explain why breast conservation improves survival despite higher locoregional recurrence?Transl Breast Cancer Res2025https://conductscience.org/library/papers/41210649PubMed
40944804Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics.Med Oncol2025https://conductscience.org/library/papers/40944804PubMed
40755423Emerging Mechanisms of Therapy Resistance in Metastatic ER+ Breast Cancer.Endocrinology2025https://conductscience.org/library/papers/40755423PubMed
40559213Natural Compounds That Target Glioma Stem Cells.NeuroSci2025https://conductscience.org/library/papers/40559213PubMed
40362664Mercury Bioaccumulation in Female Breast Cancer Is Associated to CXCR4 Expression.Int J Mol Sci2025https://conductscience.org/library/papers/40362664PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CXCR47852PubTator's text mininghttps://conductscience.org/library/genes/7852NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
WNT5A7474PubTator's text mininghttps://conductscience.org/library/genes/7474NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39875975

GET https://conductscience.org/api/papers/v1/39875975/references?page=2